TAILIEUCHUNG -   WHO Model List of  Essential Medicines for  Children  

The outcomes are available for use by educational managers in curriculum planning, or as part of quality enhancement or quality assurance processes. These would provide the core learning outcomes of a primary medical degree programme, although each country, medical school and student would also be expected to achieve additional learning outcomes tailored to their local and individual needs. If applied appropriately and linked to effective assessment, this approach allows each school or country to have a distinct profile and to focus on particular areas of strength (. research, professionalism, patient safety) while still ensuring that all of their graduates. | WHO Model List of Essential Medicines for Children 3rd list March 2011 Status of this document This is a reprint of the text on the WHO Medicines web site http medicines publications essentialmedicines en The published material is being distributed without warranty of any kind either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. WHO Model List of Essential Medicines for Children Explanatory Notes This Model List is intended for use for children up to 12 years of age. The core list presents a list of minimum medicine needs for a basic health-care system listing the most efficacious safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance and potential for safe and costeffective treatment. The complementary list presents essential medicines for priority diseases for which specialized diagnostic or monitoring facilities and or specialist medical care and or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings. The square box symbol is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases this may be the first medicine that is licensed for marketing in other instances subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data the listed medicine should be the one that is generally available at the lowest price based on international drug price information sources. Therapeutic equivalence is only indicated on

TỪ KHÓA LIÊN QUAN
TAILIEUCHUNG - Chia sẻ tài liệu không giới hạn
Địa chỉ : 444 Hoang Hoa Tham, Hanoi, Viet Nam
Website : tailieuchung.com
Email : tailieuchung20@gmail.com
Tailieuchung.com là thư viện tài liệu trực tuyến, nơi chia sẽ trao đổi hàng triệu tài liệu như luận văn đồ án, sách, giáo trình, đề thi.
Chúng tôi không chịu trách nhiệm liên quan đến các vấn đề bản quyền nội dung tài liệu được thành viên tự nguyện đăng tải lên, nếu phát hiện thấy tài liệu xấu hoặc tài liệu có bản quyền xin hãy email cho chúng tôi.
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.